Ok Biotech Co Ltd (4155) - Total Assets
Based on the latest financial reports, Ok Biotech Co Ltd (4155) holds total assets worth NT$3.89 Billion TWD (≈ $122.66 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Ok Biotech Co Ltd for net asset value and shareholders' equity analysis.
Ok Biotech Co Ltd - Total Assets Trend (2009–2024)
This chart illustrates how Ok Biotech Co Ltd's total assets have evolved over time, based on quarterly financial data.
Ok Biotech Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Ok Biotech Co Ltd's total assets of NT$3.89 Billion consist of 39.9% current assets and 60.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 7.5% |
| Accounts Receivable | NT$571.51 Million | 15.5% |
| Inventory | NT$530.53 Million | 14.4% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$124.97 Million | 3.4% |
| Goodwill | NT$353.52 Million | 9.6% |
Asset Composition Trend (2009–2024)
This chart illustrates how Ok Biotech Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Ok Biotech Co Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ok Biotech Co Ltd's current assets represent 39.9% of total assets in 2024, a decrease from 79.1% in 2009.
- Cash Position: Cash and equivalents constituted 7.5% of total assets in 2024, down from 15.8% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 12.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 15.5% of total assets.
Ok Biotech Co Ltd Competitors by Total Assets
Key competitors of Ok Biotech Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
INKON Life Technology Co Ltd
SHE:300143
|
China | CN¥4.15 Billion |
|
CareRay Digital Medical Technology Co Ltd
SHG:688607
|
China | CN¥988.48 Million |
|
Senseonics Holdings, Inc. Common Stock
NYSE MKT:SENS
|
USA | $139.92 Million |
|
Universus Photo Imagings Limited
NSE:UNIVPHOTO
|
India | Rs8.57 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
|
Aligned Genetics Inc
KQ:238120
|
Korea | ₩45.11 Billion |
|
Heramed Ltd
AU:HMD
|
Australia | AU$1.04 Million |
|
Acarix A/S
ST:ACARIX
|
Sweden | Skr48.33 Million |
Ok Biotech Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.79 | 1.85 | 1.95 |
| Quick Ratio | 1.17 | 1.25 | 1.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$614.80 Million | NT$603.51 Million | NT$622.15 Million |
Ok Biotech Co Ltd - Advanced Valuation Insights
This section examines the relationship between Ok Biotech Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.83 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | 20.5% |
| Total Assets | NT$3.70 Billion |
| Market Capitalization | $59.00 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ok Biotech Co Ltd's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Ok Biotech Co Ltd's assets grew by 20.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Ok Biotech Co Ltd (2009–2024)
The table below shows the annual total assets of Ok Biotech Co Ltd from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$3.70 Billion ≈ $116.42 Million |
+20.47% |
| 2023-12-31 | NT$3.07 Billion ≈ $96.64 Million |
+0.20% |
| 2022-12-31 | NT$3.06 Billion ≈ $96.44 Million |
+8.83% |
| 2021-12-31 | NT$2.81 Billion ≈ $88.62 Million |
+10.95% |
| 2020-12-31 | NT$2.54 Billion ≈ $79.87 Million |
+14.17% |
| 2019-12-31 | NT$2.22 Billion ≈ $69.96 Million |
+19.98% |
| 2018-12-31 | NT$1.85 Billion ≈ $58.31 Million |
-1.77% |
| 2017-12-31 | NT$1.88 Billion ≈ $59.36 Million |
+25.99% |
| 2016-12-31 | NT$1.50 Billion ≈ $47.11 Million |
+3.45% |
| 2015-12-31 | NT$1.45 Billion ≈ $45.54 Million |
+2.48% |
| 2014-12-31 | NT$1.41 Billion ≈ $44.44 Million |
-3.16% |
| 2013-12-31 | NT$1.46 Billion ≈ $45.89 Million |
+87.29% |
| 2012-12-31 | NT$777.74 Million ≈ $24.50 Million |
+59.89% |
| 2011-12-31 | NT$486.42 Million ≈ $15.32 Million |
+49.49% |
| 2010-12-31 | NT$325.39 Million ≈ $10.25 Million |
+58.98% |
| 2009-12-31 | NT$204.67 Million ≈ $6.45 Million |
-- |
About Ok Biotech Co Ltd
OK Biotech Co., Ltd. develops, manufactures, markets, and sells blood glucose monitoring systems and homecare healthcare devices in Taiwan and internationally. It also offers OTC hearing aids, multi-frequency therapy devices, and factory setup solutions. The company was founded in 2004 and is based in Hsinchu City, Taiwan.